Preservation of swallowing in resected oral cavity squamous cell carcinoma: examining radiation volume effects (PRESERVE): study protocol for a randomized phase II trial.
Adolescent
Adult
Aged
Aged, 80 and over
Canada
/ epidemiology
Chemotherapy, Adjuvant
/ adverse effects
Clinical Trials, Phase II as Topic
Combined Modality Therapy
Deglutition Disorders
/ etiology
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Neck Dissection
/ adverse effects
Neoplasm Recurrence, Local
/ diagnosis
Oropharyngeal Neoplasms
/ pathology
Prognosis
Radiotherapy
/ adverse effects
Radiotherapy Dosage
Randomized Controlled Trials as Topic
Squamous Cell Carcinoma of Head and Neck
/ pathology
Survival Rate
Young Adult
De-escalation
Head and neck cancer
Oral cavity
Quality of life
Radiotherapy
Randomized controlled trial
Recurrence
Survival
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
14 Aug 2020
14 Aug 2020
Historique:
received:
13
07
2020
accepted:
04
08
2020
entrez:
16
8
2020
pubmed:
17
8
2020
medline:
9
6
2021
Statut:
epublish
Résumé
Patients with resected oral cavity squamous cell carcinoma (OCSCC) are often treated with adjuvant radiation (RT) ± concomitant chemotherapy based on pathological findings. Standard RT volumes include all surgically dissected areas, including the tumour bed and dissected neck. RT has significant acute and long-term toxicities including odynophagia, dysphagia, dermatitis and fibrosis. The goal of this study is to assess the rate of regional failure with omission of radiation to the surgically dissected pathologically node negative (pN0) hemi-neck(s) compared to historical control, and to compare oncologic outcomes, toxicity, and quality of life (QoL) profiles between standard RT volumes and omission of RT to the pN0 neck. This is a multicentre phase II study randomizing 90 patients with T1-4 N0-2 OCSCC with at least one pN0 hemi-neck in a 1:2 ratio between standard RT volumes and omission of RT to the pN0 hemi-neck(s). Patients will be stratified based on overall nodal status (nodal involvement vs. no nodal involvement) and use of concurrent chemotherapy. The primary endpoint is regional failure in the pN0 hemi-neck(s); we hypothesize that a 2-year regional recurrence of 20% or less will be achieved. Secondary endpoints include overall and progression-free survival, local recurrence, rate of salvage therapy, toxicity and QoL. This study will provide an assessment of omission of RT to the dissected pN0 hemi-neck(s) on oncologic outcomes, QoL and toxicity. Results will inform the design of future definitive phase III trials. Clinicaltrials.gov identifier: NCT03997643 . Date of registration: June 25, 2019, Current version: 2.0 on July 11 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with resected oral cavity squamous cell carcinoma (OCSCC) are often treated with adjuvant radiation (RT) ± concomitant chemotherapy based on pathological findings. Standard RT volumes include all surgically dissected areas, including the tumour bed and dissected neck. RT has significant acute and long-term toxicities including odynophagia, dysphagia, dermatitis and fibrosis. The goal of this study is to assess the rate of regional failure with omission of radiation to the surgically dissected pathologically node negative (pN0) hemi-neck(s) compared to historical control, and to compare oncologic outcomes, toxicity, and quality of life (QoL) profiles between standard RT volumes and omission of RT to the pN0 neck.
METHODS
METHODS
This is a multicentre phase II study randomizing 90 patients with T1-4 N0-2 OCSCC with at least one pN0 hemi-neck in a 1:2 ratio between standard RT volumes and omission of RT to the pN0 hemi-neck(s). Patients will be stratified based on overall nodal status (nodal involvement vs. no nodal involvement) and use of concurrent chemotherapy. The primary endpoint is regional failure in the pN0 hemi-neck(s); we hypothesize that a 2-year regional recurrence of 20% or less will be achieved. Secondary endpoints include overall and progression-free survival, local recurrence, rate of salvage therapy, toxicity and QoL.
DISCUSSION
CONCLUSIONS
This study will provide an assessment of omission of RT to the dissected pN0 hemi-neck(s) on oncologic outcomes, QoL and toxicity. Results will inform the design of future definitive phase III trials.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov identifier: NCT03997643 . Date of registration: June 25, 2019, Current version: 2.0 on July 11 2020.
Identifiants
pubmed: 32795322
doi: 10.1186/s13014-020-01636-x
pii: 10.1186/s13014-020-01636-x
pmc: PMC7427897
doi:
Banques de données
ClinicalTrials.gov
['NCT03997643']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
196Références
Arch Otolaryngol Head Neck Surg. 2000 Apr;126(4):459-67
pubmed: 10772298
Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):529-34
pubmed: 9486600
J Clin Oncol. 2019 Oct 1;37(28):2548-2555
pubmed: 31246526
Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):870-6
pubmed: 11448365
Eur J Surg Oncol. 1996 Oct;22(5):502-4
pubmed: 8903493
Lancet Oncol. 2019 Oct;20(10):1349-1359
pubmed: 31416685
Int J Radiat Oncol Biol Phys. 1992;23(4):737-42
pubmed: 1618666
J Surg Oncol. 1988 Jun;38(2):71-6
pubmed: 3288812
BMC Cancer. 2020 Feb 14;20(1):125
pubmed: 32059705
J Laryngol Otol. 2016 May;130(S2):S83-S89
pubmed: 27841120
Acta Otorrinolaringol Esp. 2004 Nov;55(9):415-9
pubmed: 15605806
Oral Oncol. 2018 Mar;78:94-101
pubmed: 29496065
Int J Radiat Oncol Biol Phys. 1993 Jan;25(1):17-21
pubmed: 8416876
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):571-8
pubmed: 11597795
Clin Otolaryngol. 2019 Mar;44(2):131-137
pubmed: 30295408
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Br J Oral Maxillofac Surg. 2012 Sep;50(6):481-9
pubmed: 22196145
Arch Otolaryngol Head Neck Surg. 2010 Mar;136(3):225-8
pubmed: 20231637
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):362-70
pubmed: 18164833
Radiother Oncol. 2019 May;134:1-9
pubmed: 31005201
Arch Otolaryngol Head Neck Surg. 2002 Jan;128(1):44-9
pubmed: 11784253
Arch Phys Med Rehabil. 2005 Aug;86(8):1516-20
pubmed: 16084801
Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):682-8
pubmed: 20188492
Head Neck. 2005 Oct;27(10):843-50
pubmed: 16161069
Head Neck. 2018 Jan;40(1):163-169
pubmed: 29083541
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Oral Oncol. 2013 Sep;49(9):872-877
pubmed: 23830839
Cancer. 2017 Dec 1;123(23):4594-4607
pubmed: 28881377
Cancer. 2017 Jan 1;123(1):62-70
pubmed: 27564246
Acta Oncol. 1992;31(3):311-21
pubmed: 1622651
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Cancer. 2013 Mar 15;119(6):1168-76
pubmed: 23184439
BMC Cancer. 2013 Mar 20;13:133
pubmed: 23514246
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205
pubmed: 22749632
Dysphagia. 2008 Dec;23(4):392-405
pubmed: 18855050
Cancer. 2007 Jul 1;110(1):196-202
pubmed: 17546575
Cancers (Basel). 2017 Oct 06;9(10):
pubmed: 28984841
Ann Oncol. 2010 May;21 Suppl 5:v184-6
pubmed: 20555077
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894